Emerging nanomedicine strategies for hepatocellular carcinoma therapy
Abstract Hepatocellular carcinoma (HCC) is a prevalent malignant tumor with a range of risk factors, including viral infections, alcoholic liver disease, exposure to fungal toxins, obesity, and type 2 diabetes. Despite advancements in early detection and treatment, HCC continues to exhibit a high ra...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | iMetaOmics |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imo2.12 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575930529218560 |
|---|---|
| author | Chen Guo Jiayu Zhang Xiaomeng Cai Rui Dou Jiaruo Tang Zhengyuan Huang Xueting Wang Yan Guo Hanqing Chen Jun Chen |
| author_facet | Chen Guo Jiayu Zhang Xiaomeng Cai Rui Dou Jiaruo Tang Zhengyuan Huang Xueting Wang Yan Guo Hanqing Chen Jun Chen |
| author_sort | Chen Guo |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is a prevalent malignant tumor with a range of risk factors, including viral infections, alcoholic liver disease, exposure to fungal toxins, obesity, and type 2 diabetes. Despite advancements in early detection and treatment, HCC continues to exhibit a high rate of recurrence. Patients in advanced stages have a poor prognosis, and the survival rate after cancer metastasis is notably low. Consequently, there exists an urgent necessity for novel treatment strategies. Nanomedicine possesses superior attributes, such as targeted administration and responsive drug release within the tumor microenvironment. These systems demonstrate potential in HCC treatment by facilitating the transportation of diverse therapeutic drugs. This comprehensive review aims to delve into the application of nanoparticle drug delivery systems in the management of liver tumors, with particular emphasis on formulation, targeted strategies specific to liver tumors, and various methods of drug release. By offering insights into the utilization of nanoparticle drug delivery systems in the realm of liver tumor treatment, this review endeavors to assist readers in exploring their vast potential. |
| format | Article |
| id | doaj-art-a44b37a247da473ab5d4328514015984 |
| institution | Kabale University |
| issn | 2996-9506 2996-9514 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | iMetaOmics |
| spelling | doaj-art-a44b37a247da473ab5d43285140159842025-01-31T16:15:20ZengWileyiMetaOmics2996-95062996-95142024-09-0111n/an/a10.1002/imo2.12Emerging nanomedicine strategies for hepatocellular carcinoma therapyChen Guo0Jiayu Zhang1Xiaomeng Cai2Rui Dou3Jiaruo Tang4Zhengyuan Huang5Xueting Wang6Yan Guo7Hanqing Chen8Jun Chen9Department of Gastroenterology and Hepatology, Center for Medical Research on Innovation and Translation, The Second Affiliated Hospital, School of Medicine South China University of Technology Guangzhou ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaDepartment of Gastroenterology and Hepatology, Center for Medical Research on Innovation and Translation, The Second Affiliated Hospital, School of Medicine South China University of Technology Guangzhou ChinaCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi‐disciplinary Research Division Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS) Beijing ChinaAbstract Hepatocellular carcinoma (HCC) is a prevalent malignant tumor with a range of risk factors, including viral infections, alcoholic liver disease, exposure to fungal toxins, obesity, and type 2 diabetes. Despite advancements in early detection and treatment, HCC continues to exhibit a high rate of recurrence. Patients in advanced stages have a poor prognosis, and the survival rate after cancer metastasis is notably low. Consequently, there exists an urgent necessity for novel treatment strategies. Nanomedicine possesses superior attributes, such as targeted administration and responsive drug release within the tumor microenvironment. These systems demonstrate potential in HCC treatment by facilitating the transportation of diverse therapeutic drugs. This comprehensive review aims to delve into the application of nanoparticle drug delivery systems in the management of liver tumors, with particular emphasis on formulation, targeted strategies specific to liver tumors, and various methods of drug release. By offering insights into the utilization of nanoparticle drug delivery systems in the realm of liver tumor treatment, this review endeavors to assist readers in exploring their vast potential.https://doi.org/10.1002/imo2.12liver cancernanoparticlesstimulus‐responsive strategytargeting strategy |
| spellingShingle | Chen Guo Jiayu Zhang Xiaomeng Cai Rui Dou Jiaruo Tang Zhengyuan Huang Xueting Wang Yan Guo Hanqing Chen Jun Chen Emerging nanomedicine strategies for hepatocellular carcinoma therapy iMetaOmics liver cancer nanoparticles stimulus‐responsive strategy targeting strategy |
| title | Emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| title_full | Emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| title_fullStr | Emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| title_full_unstemmed | Emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| title_short | Emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| title_sort | emerging nanomedicine strategies for hepatocellular carcinoma therapy |
| topic | liver cancer nanoparticles stimulus‐responsive strategy targeting strategy |
| url | https://doi.org/10.1002/imo2.12 |
| work_keys_str_mv | AT chenguo emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT jiayuzhang emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT xiaomengcai emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT ruidou emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT jiaruotang emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT zhengyuanhuang emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT xuetingwang emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT yanguo emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT hanqingchen emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy AT junchen emergingnanomedicinestrategiesforhepatocellularcarcinomatherapy |